Gastrointestinal disturbances and their management in miglustat-treated patients

@article{Belmatoug2011GastrointestinalDA,
  title={Gastrointestinal disturbances and their management in miglustat-treated patients},
  author={Nadia Belmatoug and Alberto B. Burlina and Pilar Giraldo and Christian J. Hendriksz and David J Kuter and Eugen Mengel and Gregory McCarthy Pastores},
  journal={Journal of Inherited Metabolic Disease},
  year={2011},
  volume={34},
  pages={991-1001}
}
Miglustat (Zavesca®) is approved for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease (GD1) for whom enzyme replacement therapy is unsuitable, and for the treatment of progressive neurological manifestations in adult and paediatric patients with Niemann-Pick disease type C (NP-C). Gastrointestinal disturbances such as diarrhoea, flatulence and abdominal pain/discomfort have consistently been reported as the most frequent adverse events associated with miglustat… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Pharmacotherapy of Gaucher Disease: Current and Future Options.

P & T : a peer-reviewed journal for formulary management • 2018

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Dietary modifications in patients receiving miglustat

Journal of Inherited Metabolic Disease • 2010
View 6 Excerpts
Highly Influenced

Long-term miglustat therapy in children with Niemann-Pick disease type C.

Journal of child neurology • 2010
View 10 Excerpts
Highly Influenced

Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a postauthorisation safety surveillance programme

CE Hollak, D Hughes, IN van Schaik
Pharmacoepidemiol Drug Saf • 2009
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…